<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829110</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2021-0246</org_study_id>
    <nct_id>NCT04829110</nct_id>
  </id_info>
  <brief_title>Alcohol Induced de Novo Lipogenesis in Women</brief_title>
  <official_title>Alcohol Induced de Novo Lipogenesis in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is cross-sectional is design. In the first Aim of this study, 5 women and 5 men&#xD;
      will be asked to consume 2g/kg of [2H]water (a.k.a. deuterium oxide or heavy water) which&#xD;
      incorporates 2H tracers into newly synthesized fatty acids and triglycerides. Deuterated&#xD;
      water is not radioactive and has a long history of application in human studies. Researchers&#xD;
      will collect blood samples 2 hours before and 5 hours after the participants consume 20 grams&#xD;
      of alcohol as vodka to measure alcohol induced hepatic de novo lipogenesis (DNL) in both men&#xD;
      in women. In addition, for Aim 2 researchers will recruit an additional 10 women who will be&#xD;
      randomized into one of two groups who will consume a beverage containing vodka and sucrose,&#xD;
      or sucrose alone. Aim 2 will be identical to the experimental scheme in Aim 2 in order to&#xD;
      determine if sucrose enhances the effects of vodka on hepatic DNL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hepatic De Novo Lipogenesis (DNL)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, and 7 hours post heavy water consumption</time_frame>
    <description>DNL will be measured by Orbitrap high-resolution-mass-spectrometry (GC-Orbitrap-HRMS)&#xD;
We will measure changes in the incorporation of 2H tracers into plasma triglycerides over time. This data will be analyzed by averaging each time point and looking at change in de novo lipogenesis over time.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Metabolism</condition>
  <arm_group>
    <arm_group_label>A. ETOH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Males and 5 Females will receive deuterated water and drink 2.15 ounces of alcohol in the form of vodka and have de novo Lipogenesis measured at 11 time points during and after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETOH + Sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Females will receive deuterated water and drink 1.72 ounces of alcohol in the form of vodka + 7 grams of sucrose and have de novo Lipogenesis measured at 11 time points during and after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. Sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Females will receive deuterated water and drink a solution containing water and 35 grams of sucrose, and have de novo Lipogenesis measured at 11 time points during and after.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ETOH</intervention_name>
    <description>Participants will consume Vodka</description>
    <arm_group_label>A. ETOH</arm_group_label>
    <arm_group_label>ETOH + Sucrose</arm_group_label>
    <other_name>Vodka</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sucrose</intervention_name>
    <description>Participants will consume sucrose in solution with water</description>
    <arm_group_label>C. Sucrose</arm_group_label>
    <arm_group_label>ETOH + Sucrose</arm_group_label>
    <other_name>Sucrose solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Ages 21 - 45&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Light to moderate alcohol consumption (≤1 drink a day (~14g) in women and ≤2 drinks a&#xD;
             day (~28 g) in men)&#xD;
&#xD;
          -  BMI between 18.5-29.9&#xD;
&#xD;
          -  Normal Nutritional Status&#xD;
&#xD;
          -  Ability to speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;29.9&#xD;
&#xD;
          -  Comorbid conditions&#xD;
&#xD;
          -  Any regular medications, except Oral Contraceptives&#xD;
&#xD;
          -  Pregnant or Breastfeeding&#xD;
&#xD;
          -  Regular exercise above activities of daily living&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justin Fletcher, PhD</last_name>
    <phone>913-314-4274</phone>
    <email>justin.fletcher@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy H Christie, BSN, RN</last_name>
    <phone>214-648-3394</phone>
    <email>lucy.christie@utsouthwestern.edu</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Justin Fletcher</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

